Sientra settles public offering lawsuits for $10.9 million

Goleta-based breast implant manufacturer Sientra announced a $10.9 million settlement Oct. 28 in two lawsuits that shareholders filed over the timing of the second public offering the company held in September 2015. Sientra announced in a news release that the company will pay $10.9 million to six parties in cases in federal court in Los Read More →
Sientra CFO resigns, new CFO named

Embattled-breast implant manufacturer Sientra said in a news release Oct. 27 that Chief Financial Officer Matthew Pigeon stepped down from his position “to pursue other opportunities.” Patrick Williams, who most recently served as CFO of Pleasanton-based ZELTIQ Aesthetics from November 2012 until this past April, will fill Pigeon’s roll as CFO at Sientra. Williams also Read More →

Sientra finds new factory to make breast implants

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Goleta’s Sientra lines up new manufacturer for breast implants

Eleven months after manufacturing of its silicone breast implants stopped because it’s Brazilian factory was alleged to have unsafe manufacturing conditions, Sientra announced an agreement with a domestic manufacturer to make its implants Aug. 9. Sientra will use Vesta, a unit of Ohio-based tech conglomerate Lubrizol LifeSciences, which is owned by Berkshire Hathaway. CEO Jeffrey Read More →

Sientra selling implants again but staff cut as losses mount

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Breast implant maker Sientra loses $11.9 million in first quarter

Sientra, the Goleta-based breast implant company which resumed sales in March after suspending them last fall, posted a loss of $11.9 million for the first quarter. With its core products back on the market after a months long hiatus, the company said it hopes that resumption of marketing efforts will help it resume its prior Read More →